Analysts have been eager to weigh in on the Healthcare sector with new ratings on aTyr Pharma (ATYR – Research Report), Crispr Therapeutics AG ...

LOS ANGELES, CA / ACCESS Newswire / February 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

Early this month, the Humira maker said that the non-cash charge reflected two failed mid-stage trials designed to evaluate Cerevel Therapeutics' lead drug, emraclidine, in schizophrenia.

Pressure has been growing on Skyrizi and Rinvoq to drive sales after a schizophrenia drug Abbvie acquired in its $8.7 billion buyout of Cerevel Therapeutics Inc. failed in clinical trials.

LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced ...

Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...

BOSTON, Jan. 27, 2025 /PRNewswire/ -- Averna Therapeutics, Inc. ("Averna"; formerly known as Exsilio Therapeutics, Inc.), a biotechnology company developing genomic medicines that insert ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...

AbbVie bought Cerevel last year for $8.7 billion ... Lilly has also agreed to buy Scorpion Therapeutics, a private biotech developing cancer treatments, for up to $2.5 billion. ‘Lilly has been very ...

Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of ...

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.